Epac activation with 8CPT-AM induced RLC phosphorylation in the perfused hearts. by Yoshiki Ohnuki (576298)

Subjects:

VR training system for radiopharmaceutical administration. by Akihiro Kakimoto (343218)

Subjects:

Difference in by Akihiro Kakimoto (343218)

Subjects:

Experimental protocol. by Akihiro Kakimoto (343218)

Subjects:

Relationship between the change in by Akihiro Kakimoto (343218)

Subjects:

Changes in blood pressure, HbA1c, blood lipid and liver function-related indicator values compared with baseline values in all patients over time. by Jia Song (495396)

Subjects:

Each subfigure shows a different local size (LS) and context size (CS) configuration, where the reliability of the model across different initializations is measured in R-squared. by Eloy Geenjaar (21533195)

Subjects:

A pulse of TNF-alpha halts the growth of <i>L</i>. <i>intracellularis</i> in-vitro. by Huan W. Yang (19746645)

Subjects:

Particle size distribution of GO-GA NPs. by Huda H. Elbehery (22492996)

Subjects:

GC-MS chromatogram of garlic essential oil. by Huda H. Elbehery (22492996)

Subjects:

Post-effect of GO and GO-GA NPs on progeny production of <i>Callosobruchus maculatus.</i> by Huda H. Elbehery (22492996)

Subjects:

Particle size distribution, PDI, and zeta potential of GO-GA NPs. by Huda H. Elbehery (22492996)

Subjects:

Volatile constituents of Garlic essential oil identified by GC-MS. by Huda H. Elbehery (22492996)

Subjects:

Fourier-transform infrared spectroscopy (FTIR) spectra of GA (black), GO (blue), and GO–GA NPs (red). by Huda H. Elbehery (22492996)

Subjects:

Toxicity of GO and GO-GA NPs on <i>C. maculatus</i> adults after 24h exposure. by Huda H. Elbehery (22492996)

Subjects:

PT₅₀ values of GO and GO-GA NPs against <i>Callosobruchus maculatus.</i> by Huda H. Elbehery (22492996)

Subjects:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Stereotactic injection of AAV-miR-129-5p attenuated microglia activation in depressed mice. by Qiaozhen Qin (13159201)

Subjects: